The ATAD3A Knockout TE1 Polyclonal Cells provide a CRISPR/Cas9-mediated gene disruption tool targeting ATAD3A in the human esophageal squamous cell carcinoma line TE1. Supplied as a polyclonal knockout population, this product avoids clonal selection biases and enables pooled loss-of-function analyses. The polyclonal format captures heterogeneous editing outcomes while establishing a stable functional knockout model for downstream experiments.
The TE1 host cell line originates from a poorly differentiated esophageal squamous cell carcinoma resected from a Japanese patient and is widely employed as a model for esophageal cancer biology. TE1 cells maintain characteristic epithelial morphology and exhibit dysregulated Wnt/??-catenin and mTORC1 signaling pathways, reflecting key oncogenic drivers in ESCC. This genetic background provides a pertinent system for evaluating gene function in the context of esophageal malignancy, particularly for proliferation, apoptosis, and mitochondrial biology studies.
ATAD3A encodes a mitochondrial inner membrane ATPase central to mitochondrial dynamics, cholesterol homeostasis, and cell proliferation. It is transcriptionally controlled by c-MYC and HSF1 and functions downstream of growth signals to promote ??-catenin nuclear translocation, activating TCF/LEF target genes, and to stimulate mTORC1/S6K signaling. ATAD3A interacts with mitochondrial fusion factors MFN2 and OPA1, HSP60, GSK3??, and MICOS complex components, coordinating organelle shape and metabolic output. Loss of ATAD3A disrupts mitochondrial networks and induces apoptosis.
In the TE1 esophageal cancer context, ATAD3A is thought to promote tumorigenesis by reinforcing ??-catenin nuclear translocation and mTORC1/S6K activity. The polyclonal knockout cells allow researchers to dissect how ATAD3A loss impairs mitochondrial integrity, attenuates TCF/LEF-mediated transcription, and triggers apoptotic programs. This model is instrumental for examining the reliance of esophageal carcinoma cells on ATAD3A-driven mitochondrial and signaling functions, and for assessing the therapeutic potential of targeting ATAD3A in ESCC.
Key applications include western blotting and RT-qPCR for knockout validation, immunofluorescence for mitochondrial morphology assessment, TCF/LEF luciferase reporter assays, and Seahorse metabolic profiling. Colony formation and apoptosis assays quantify functional consequences of ATAD3A loss, while migration assays evaluate metastatic potential. This product supports studies in esophageal cancer biology, mitochondrial dysfunction, drug target validation, and proliferation/apoptosis mechanisms. For further details, contact Ascent Research.
